Orgenesis Inc. (ORGS) Expected to Post Quarterly Sales of $7.78 Million

Equities analysts expect Orgenesis Inc. (NYSE:ORGS) to post sales of $7.78 million for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates for Orgenesis’ earnings. The lowest sales estimate is $7.56 million and the highest is $8.00 million. The firm is expected to report its next earnings results on Wednesday, February 27th.

According to Zacks, analysts expect that Orgenesis will report full-year sales of $20.63 million for the current year, with estimates ranging from $20.41 million to $20.85 million. For the next fiscal year, analysts forecast that the firm will post sales of $39.08 million, with estimates ranging from $32.66 million to $45.50 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Orgenesis.

Separately, Dawson James reissued a “buy” rating on shares of Orgenesis in a research report on Thursday, December 20th.

ORGS stock traded up $0.09 during mid-day trading on Friday, hitting $4.87. 19,500 shares of the company were exchanged, compared to its average volume of 24,230. Orgenesis has a 12-month low of $3.87 and a 12-month high of $16.80.

About Orgenesis

Orgenesis Inc, a service and research company, focus on the development and manufacture of cell therapy for advanced medicinal products in the field of regenerative medicine industry. It operates through two segments, Contract Development and Manufacturing Organizations (CDMO) and Cellular Therapy (CT) Business.

Further Reading: How to interpret a stock’s beta number

Get a free copy of the Zacks research report on Orgenesis (ORGS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Orgenesis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Orgenesis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit